PURPOSE: We investigated potential associations between single-nucleotide polymorphisms (SNPs) in the heat shock protein beta-1 (HSPB1) gene and overall survival in US patients with non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Using available genomic DNA samples from 224 patients with NSCLC treated with definitive radio(chemo)therapy, we genotyped 2 SNPs of HSPB1 (NCBI SNP nos. rs2868370 and rs2868371). We used both Kaplan-Meier cumulative probability and Cox proportional hazards analyses to evaluate the effect of HSPB1 genotypes on survival. RESULTS: Our cohort consisted of 117 men and 107 women, mostly white (79.5%), with a median age of 70 years. The median radiation dose was 66 Gy (range, 63-87.5 Gy), and 183 patients (82%) received concurrent platinum-based chemotherapy. The most common genotype of the rs2868371 SNP was CC (61%). Univariate and multivariate analyses showed that this genotype was associated with poorer survival than CG and GG genotypes (univariate hazard ratio [HR] = 1.39, 95% confidence interval [CI], 1.02-1.90; P=.037; multivariate HR = 1.39; 95% CI, 1.01-1.92; P=.045). CONCLUSIONS: Our results showed that the CC genotype of HSPB1 rs2868371 was associated with poorer overall survival in patients with NSCLC after radio(chemo)therapy, findings that contradict those of a previous study of Chinese patients. Validation of our findings with larger numbers of similar patients is needed, as are mechanical and clinical studies to determine the mechanism underlying these associations. Published by Elsevier Inc.
PURPOSE: We investigated potential associations between single-nucleotide polymorphisms (SNPs) in the heat shock protein beta-1 (HSPB1) gene and overall survival in US patients with non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Using available genomic DNA samples from 224 patients with NSCLC treated with definitive radio(chemo)therapy, we genotyped 2 SNPs of HSPB1 (NCBI SNP nos. rs2868370 and rs2868371). We used both Kaplan-Meier cumulative probability and Cox proportional hazards analyses to evaluate the effect of HSPB1 genotypes on survival. RESULTS: Our cohort consisted of 117 men and 107 women, mostly white (79.5%), with a median age of 70 years. The median radiation dose was 66 Gy (range, 63-87.5 Gy), and 183 patients (82%) received concurrent platinum-based chemotherapy. The most common genotype of the rs2868371 SNP was CC (61%). Univariate and multivariate analyses showed that this genotype was associated with poorer survival than CG and GG genotypes (univariate hazard ratio [HR] = 1.39, 95% confidence interval [CI], 1.02-1.90; P=.037; multivariate HR = 1.39; 95% CI, 1.01-1.92; P=.045). CONCLUSIONS: Our results showed that the CC genotype of HSPB1rs2868371 was associated with poorer overall survival in patients with NSCLC after radio(chemo)therapy, findings that contradict those of a previous study of Chinese patients. Validation of our findings with larger numbers of similar patients is needed, as are mechanical and clinical studies to determine the mechanism underlying these associations. Published by Elsevier Inc.
Authors: M C Guisasola; F Calvo; P Marcos; I Simón; F J Villanueva; E Andrés; A Suárez; P García-Barreno Journal: Int J Radiat Biol Date: 2006-03 Impact factor: 2.694
Authors: H I Yoon; E K Silverman; H W Lee; C G Yoo; C T Lee; H S Chung; Y W Kim; S K Han; Y S Shim; J J Yim Journal: Int J Tuberc Lung Dis Date: 2006-05 Impact factor: 2.373
Authors: Jehonathan H Pinthus; Inna Bryskin; John Trachtenberg; Jiang-Ping Lu; Gurmit Singh; Eduard Fridman; Brian C Wilson Journal: Neoplasia Date: 2007-01 Impact factor: 5.715
Authors: Beatriz Pontes; Francisco Núñez; Cristina Rubio; Alberto Moreno; Isabel Nepomuceno; Jesús Moreno; Jon Cacicedo; Juan Manuel Praena-Fernandez; German Antonio Escobar Rodriguez; Carlos Parra; Blas David Delgado León; Eleonor Rivin Del Campo; Felipe Couñago; Jose Riquelme; Jose Luis Lopez Guerra Journal: Rep Pract Oncol Radiother Date: 2021-12-30